Mather Group LLC. Makes New Investment in iShares Biotechnology ETF (NASDAQ:IBB)

Mather Group LLC. acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 423 shares of the financial services provider’s stock, valued at approximately $57,000.

Other large investors also recently modified their holdings of the company. International Assets Investment Management LLC bought a new stake in shares of iShares Biotechnology ETF in the fourth quarter worth $76,425,000. Itau Unibanco Holding S.A. acquired a new stake in shares of iShares Biotechnology ETF in the 3rd quarter valued at about $48,242,000. Raymond James Financial Services Advisors Inc. raised its stake in shares of iShares Biotechnology ETF by 8.9% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 153,692 shares of the financial services provider’s stock valued at $20,879,000 after purchasing an additional 12,611 shares in the last quarter. Stifel Financial Corp lifted its position in shares of iShares Biotechnology ETF by 11.7% during the fourth quarter. Stifel Financial Corp now owns 137,897 shares of the financial services provider’s stock worth $18,736,000 after purchasing an additional 14,457 shares during the last quarter. Finally, Gray Foundation acquired a new position in iShares Biotechnology ETF in the fourth quarter worth about $17,890,000. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ IBB opened at $137.34 on Monday. The stock’s 50 day moving average price is $133.17 and its two-hundred day moving average price is $134.47. iShares Biotechnology ETF has a 52-week low of $111.83 and a 52-week high of $141.16.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.